Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 8/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 8/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12843923 | 1.00 | SLC7A5 (0.48) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL398124 | 1.00 | SLC7A5 (0.48) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29957288 | 1.00 | SLC7A5 (0.48) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2030960 | 1.00 | SLC7A5 (0.48) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL1536307 | 0.98 | SLC7A5 (0.46) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL25661066 | 0.83 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL31369938 | 0.83 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL30062853 | 0.83 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL8715906 | 0.80 | SLC7A5 (0.46) | SLC7A5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31369953 | 0.80 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109465-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2009-10-21 | — | — | EP | claimed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | claimed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| EP-0175180-A1 | Histargin-related compounds, a process for their preparation and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1986-03-26 | — | — | EP | claimed |
| EP-0105193-A2 | Spergualin-related compounds, processes for the preparation thereof and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-04-11 | — | — | EP | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | ENSYSCE BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-12384744-B2 | Enzyme-cleavable methadone prodrugs and methods of use thereof | Ensysce Biosciences Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| EP-0175180-A1 | Histargin-related compounds, a process for their preparation and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1986-03-26 | — | — | EP | disclosed |
| US-4529549-A | Compound containing guanidine and amino groups | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0105193-A2 | Spergualin-related compounds, processes for the preparation thereof and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SLC7A5 921/4885GABRP 1893/4885GABRD 2748/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SLC7A5 1405/4885GABRP 3641/4885GABRD 4731/4885 |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | SLC7A5 260/4885GABRP 340/4885GABRD 1029/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SLC7A5 1050/4885GABRP 2355/4885GABRD 4276/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | SLC7A5 789/4885GABRP 734/4885GABRD 964/4885 |
| US-12384744-B2 | Enzyme-cleavable methadone prodrugs and methods of use thereof | CES2, ACHE, COMT | SLC7A5 2717/4885GABRP 1072/4885GABRD 919/4885 |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | CES2, ACHE, COMT | SLC7A5 2717/4885GABRP 1072/4885GABRD 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.